Immune checkpoint inhibitor as a therapeutic choice for double cancer: A case series

Hiroshi Aoki; Naoki Matsumoto; Hiroshi Takahashi; Masayuki Honda; Tomohiro Kaneko; Shuhei Arima; Tomotaka Ishii; Taku Mizutani; Ryota Masuzaki; Kazushige Nirei; Hiroaki Yamagami; Masahiro Ogawa; Tatsuo Kanda; Mitsuhiko Moriyama; Katsuhiro Miura

doi:10.21873/anticanres.15442

Immune checkpoint inhibitor as a therapeutic choice for double cancer: A case series

Hiroshi Aoki, Naoki Matsumoto, Hiroshi Takahashi, Masayuki Honda, Tomohiro Kaneko, Shuhei Arima, Tomotaka Ishii, Taku Mizutani, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami, Masahiro Ogawa, Tatsuo Kanda, Mitsuhiko Moriyama, Katsuhiro Miura

School of Medicine

Nihon University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) can still be used for various malignancies. Here, we present cases of double cancers including HCC treated with ICIs. Case Report: Case 1: A 70-year-old man with lung cancer and 80-mm HCC underwent nivolumab therapy. The sizes of both cancers remained constant for nine months. Case 2: A 58-year-old man with pharyngeal cancer and HCC. Nivolumab was administered, but was withdrawn after one session because of progressive disease. Case 3: A 71-year-old man with a 5 cm HCC invading the inferior vena cava, and early esophageal cancer. HCC showed a significant volume reduction and esophageal cancer demonstrated slight improvement by atezolizumab and bevacizumab therapy. Conclusion: A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.

Original language	English
Pages (from-to)	6225-6230
Number of pages	6
Journal	Anticancer Research
Volume	41
Issue number	12
DOIs	https://doi.org/10.21873/anticanres.15442
Publication status	Published - Dec 2021

Keywords

Atezolizumab
Hepatocellular carcinoma
Immune checkpoint inhibitor
Multiple primary malignancies
Nivolumab
Squamous cell carcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15442

Cite this

@article{b5026a88fedc435f94db22a131f060fa,

title = "Immune checkpoint inhibitor as a therapeutic choice for double cancer: A case series",

abstract = "Background: Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) can still be used for various malignancies. Here, we present cases of double cancers including HCC treated with ICIs. Case Report: Case 1: A 70-year-old man with lung cancer and 80-mm HCC underwent nivolumab therapy. The sizes of both cancers remained constant for nine months. Case 2: A 58-year-old man with pharyngeal cancer and HCC. Nivolumab was administered, but was withdrawn after one session because of progressive disease. Case 3: A 71-year-old man with a 5 cm HCC invading the inferior vena cava, and early esophageal cancer. HCC showed a significant volume reduction and esophageal cancer demonstrated slight improvement by atezolizumab and bevacizumab therapy. Conclusion: A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.",

keywords = "Atezolizumab, Hepatocellular carcinoma, Immune checkpoint inhibitor, Multiple primary malignancies, Nivolumab, Squamous cell carcinoma",

author = "Hiroshi Aoki and Naoki Matsumoto and Hiroshi Takahashi and Masayuki Honda and Tomohiro Kaneko and Shuhei Arima and Tomotaka Ishii and Taku Mizutani and Ryota Masuzaki and Kazushige Nirei and Hiroaki Yamagami and Masahiro Ogawa and Tatsuo Kanda and Mitsuhiko Moriyama and Katsuhiro Miura",

year = "2021",

month = dec,

doi = "10.21873/anticanres.15442",

language = "English",

volume = "41",

pages = "6225--6230",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - Immune checkpoint inhibitor as a therapeutic choice for double cancer

T2 - A case series

AU - Aoki, Hiroshi

AU - Matsumoto, Naoki

AU - Takahashi, Hiroshi

AU - Honda, Masayuki

AU - Kaneko, Tomohiro

AU - Arima, Shuhei

AU - Ishii, Tomotaka

AU - Mizutani, Taku

AU - Masuzaki, Ryota

AU - Nirei, Kazushige

AU - Yamagami, Hiroaki

AU - Ogawa, Masahiro

AU - Kanda, Tatsuo

AU - Moriyama, Mitsuhiko

AU - Miura, Katsuhiro

PY - 2021/12

Y1 - 2021/12

N2 - Background: Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) can still be used for various malignancies. Here, we present cases of double cancers including HCC treated with ICIs. Case Report: Case 1: A 70-year-old man with lung cancer and 80-mm HCC underwent nivolumab therapy. The sizes of both cancers remained constant for nine months. Case 2: A 58-year-old man with pharyngeal cancer and HCC. Nivolumab was administered, but was withdrawn after one session because of progressive disease. Case 3: A 71-year-old man with a 5 cm HCC invading the inferior vena cava, and early esophageal cancer. HCC showed a significant volume reduction and esophageal cancer demonstrated slight improvement by atezolizumab and bevacizumab therapy. Conclusion: A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.

AB - Background: Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) can still be used for various malignancies. Here, we present cases of double cancers including HCC treated with ICIs. Case Report: Case 1: A 70-year-old man with lung cancer and 80-mm HCC underwent nivolumab therapy. The sizes of both cancers remained constant for nine months. Case 2: A 58-year-old man with pharyngeal cancer and HCC. Nivolumab was administered, but was withdrawn after one session because of progressive disease. Case 3: A 71-year-old man with a 5 cm HCC invading the inferior vena cava, and early esophageal cancer. HCC showed a significant volume reduction and esophageal cancer demonstrated slight improvement by atezolizumab and bevacizumab therapy. Conclusion: A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.

KW - Atezolizumab

KW - Hepatocellular carcinoma

KW - Immune checkpoint inhibitor

KW - Multiple primary malignancies

KW - Nivolumab

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85120501908&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15442

DO - 10.21873/anticanres.15442

M3 - Article

C2 - 34848477

AN - SCOPUS:85120501908

SN - 0250-7005

VL - 41

SP - 6225

EP - 6230

JO - Anticancer Research

JF - Anticancer Research

IS - 12

ER -

Immune checkpoint inhibitor as a therapeutic choice for double cancer: A case series

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this